Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today that the Company has taken significant steps to reduce overhead and conserve liquidity as it continues operations while assessing strategic options. These options include securing additional funding and exploring business alternatives that may include partnering, acquiring, investing in or combining with businesses that may or may not be in a related industry. No assurances can be given that any of these initiatives will occur.
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three months and full year ended December 31, 2019.
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its 2019 fourth quarter and year-end financial results on Thursday, March 19, 2020, after the close of the U.S. financial markets.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Second Sight Medical Products, Inc. (NASDAQ:EYES) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, ...
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the departure of Will McGuire, President and Chief Executive Officer ("CEO"), effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board.
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Companies In The News Are: KNSA, EYEG, VBIV, EYES
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that in response to the impact of the global COVID-19 pandemic on its ability to secure financing, the Company will lay off approximately 84 of its 108 employees effective March 31, 2020. The impacted employees will be eligible for unemployment benefits subject to local regulations. Against a background of unprecedented economic shock caused by the COVID-19 pandemic and inability to secure additional financing, the Company’s Board of Directors has evaluated strategic alternatives and decided to pursue an orderly wind down of the Company’s operations. The Company intends to retain an adviser experienced in winding down operations to guide the board on next steps. Any wind down activity, if implemented, will be subject to uncertainties. Additional layoffs are expected to be made at a later date based on the Company’s level of operations.
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of an underwritten public offering of 7,500,000 shares of common stock, no par value (the "Common Stock") at an offering price of $1.00 per share of Common Stock for aggregate gross proceeds of $7,500,000, prior to deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on May 5, 2020, subject to the satisfaction of customary closing conditions.
Q4 2019 Second Sight Medical Products Inc Earnings Call
In 2015 Jonathan McGuire was appointed CEO of Second Sight Medical Products, Inc. (NASDAQ:EYES). This analysis aims...
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Q3 2019 Second Sight Medical Products Inc Earnings Call
Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it closed its previously announced underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate gross proceeds of $7,500,000, prior to deducting underwriting discounts, commissions and other offering expenses.
If you want to know who really controls Second Sight Medical Products, Inc. (NASDAQ:EYES), then you'll have to look at...
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.